GET THE APP

Concept of Substantial Similarity In Pharmaceutical Patent Infringement Cases and the Implications of Section 3d of Indian Patent Act | Abstract

Asian Journal of Pharmaceutical Technology and Innovation (ajpti)

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Concept of Substantial Similarity In Pharmaceutical Patent Infringement Cases and the Implications of Section 3d of Indian Patent Act

Abstract

Dr. Shuchi Midha*1, Aditi Midha2

 The research paper discusses the main aspects of Section 3(d) of

the Indian Patent Act 1970 with respect to the Indian
pharmaceutical industry. Three cases viz. the Novartis Glivec,
Pfizer’s Sutent and GSK’s Tykerb have been discussed that
explicitly demonstrate, pharmaceutical inventions rarely relate to
new chemical entities or novel active ingredients that have never
before been available for therapeutic use, thus encouraging
pharmaceutical companies to prolong patent protection by
obtaining separate patents on multiple attributes of a single
product. Section 3(d), whereby, regulates the granting of
pharmaceutical product patents by limiting the scope of
protection available for derivatives and new uses of a known
substance, thereby preventing patents on trivial modifications of
known substances. Thus, India’s Section 3(d) should be viewed as
a “public health safeguard” that aims to prevent “evergreening,”
and not a radical departure from international practices.

Share this article

tempobet

tempobet giriş

tempobet giriş

paper.io

agar io

wowcappadocia.com cappadocia tours
cappadocia-hotels.com cappadocia hotels
caruscappadocia.com cappadocia hotel
brothersballoon.com cappadocia balloon
balloon-rides.net cappadocia balloon flights

wormax io